Can a new weekly shot beat semaglutide for diabetes control?

NCT ID NCT06649344

Completed Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 3 trial compares an experimental once-weekly injection, HRS9531, to the established drug semaglutide in adults with type 2 diabetes that is not well controlled by metformin alone or with SGLT2 inhibitors. The study will measure changes in blood sugar levels and body weight over 36 and 52 weeks. The goal is to see if HRS9531 offers better glucose control and weight management than semaglutide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental once-weekly injection called HRS9531
What this could lead to: If HRS9531 outperforms semaglutide, it could offer a new, more effective option for managing type 2 diabetes and supporting weight loss.
What could go wrong: This is an early-phase 3 trial, so results may not confirm superiority. Side effects typical of this drug class, such as nausea or gastrointestinal issues, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Zhu Xianyi Memorial Hospital,Tianjin Medical University

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.